JPRN-UMIN000008638已完成4 期
Evaluation on efficacy and safety of a combination therapy of rituximab with bendamustin in the patients with relapsed or resistnat low grade B-cell non-Hodgkin lymphoma - Evaluation on efficacy and safety of a combination therapy of rituximab with bendamustin in the patients with relapsed or resistnat low grade B-cell non-Hodgkin lymphoma
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) infected definitely 2) critical complication (liver failure or renal failure) 3) critical complication of heart disease 4) critical complication of bowel disease 5) positive for HBsAb, HCVAb, or HIVAb 6) critical hemostatic disease 7) involved in CNS 8) febrile >38C (except for tumor fever) 9) critical complication of respiratory disease 10) concomittent presence of another malignancy 11) AIHA 12) allergy of bendamustine 13) pregnant or breast-feeding 14) allergy of rituximab 15) uncontrol of contraception 16) not eligible for this study
研究者
相似试验
招募中
不适用
Evaluation of efficacy and safety of combinationtherapy with trastuzumab and eribulin for HER2-positive inoperableness or metastatic breast cancerJPRN-UMIN000007113Wakayama Medical University Department of Thoracic and Cardiovascular Surgery35
招募中
2 期
Evaluation of the safety and efficacy of combination of neostigmine and ketorolac added to reduced local anesthetic mixture dose through medial canthus injection in vitrectomy surgeryAnaesthesiaPACTR202204650206424Research institute of Ophthalmology50
招募中
不适用
The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancerJPRN-UMIN000014099Gunma University20
已完成
不适用
The evaluation for safety and efficacy of combination therapy of adoptive immune-cell therapy with chemoradiotherapy for locally advanced esophageal cancerocally advanced esophageal cancerJPRN-UMIN000017350Gunma University6
招募中
2 期
Clinical study on VAMHA and MYRHA Tablets in Polycystic ovary syndromeCTRI/2022/12/048147Gynoveda Femtech Pvt. Ltd